Study of AQX-1125 on induced airway inflammation / healthy volunteers.

• Research type

  Research Study

• Full title

  A Phase 1, Randomized, Double-Blind, Placebo-Controlled, 2 Cohort, 2-Way Crossover Study in Healthy Volunteers to Evaluate the Effect of Multiples Doses of AQX-1125 on Cellular and Biochemical Changes in Sputum Following an Inhaled Lipopolysaccharide (LPS) Challenge.

• IRAS ID

  87565

• Contact name

  Stephen Smith

• Sponsor organisation

  Aquinox

• Eudract number

  2011-003837-33

• Research summary

  AQX-1125 is being developed for the treatment of inflammatory respiratory diseases such as asthma, chronic obstructive pulmonary disease (COPD), and allergic rhinitis. Based on animal and other study data, it is proposed that AQX-1125 may be able to reduce inflammatory cell responses and may provide a therapeutic benefit in the treatments of these conditions.The trial will involve comparing the effect of AQX-1125 to that of placebo on the airway inflammation produced by getting healthy volunteers to inhale an irritating substance (lipo-polysaccharide - LPS).Two doses are planned in two groups of healthy volunteers. Group 1 will start with 450mg per day. Thereafter repeating or reducing this dose for group 2.

• REC name

  HSC REC B

• REC reference

  11/NI/0134

• Date of REC Opinion

  6 Oct 2011

• REC opinion

  Further Information Favourable Opinion